EAPHARMA
Status timeline
- 19 Jan 2024Application filedNew Application Entered
- 14 Aug 2024Assigned to an examining attorneyAssigned To Examiner
- 14 Aug 2024Office action issuedNon-Final Action Written
- 25 Oct 2024Response to office action filedTeas Response To Office Action Received
- 19 Nov 2024Examination suspendedSuspension Letter Written
- 20 Jul 2026Approved for publicationApproved For Pub - Principal Register
- 18 Aug 2026Published for oppositionPublished For Opposition
All 23 USPTO events
| 2026-08-18 | Published For Opposition |
| 2026-08-18 | Official Gazette Publication Confirmation E-Mailed |
| 2026-08-12 | Notification Of Notice Of Publication E-Mailed |
| 2026-07-20 | Approved For Pub - Principal Register |
| 2026-06-08 | Suspension Checked - To Attorney For Action |
| 2025-12-09 | Report Completed Suspension Check Case Still Suspended |
| 2025-06-17 | Teas Revoke/App/Change Addr Of Atty/Dom Rep Received |
| 2025-06-17 | Attorney/Dom.rep.revoked And/Or Appointed |
| 2025-06-17 | Teas Change Of Correspondence Received |
| 2025-06-02 | Report Completed Suspension Check Case Still Suspended |
| 2024-11-19 | Suspension Letter Written |
| 2024-11-19 | Letter Of Suspension E-Mailed |
| 2024-11-19 | Notification Of Letter Of Suspension E-Mailed |
| 2024-10-25 | Teas Response To Office Action Received |
| 2024-10-25 | Correspondence Received In Law Office |
| 2024-10-25 | Teas/Email Correspondence Entered |
| 2024-08-14 | Assigned To Examiner |
| 2024-08-14 | Non-Final Action Written |
| 2024-08-14 | Non-Final Action E-Mailed |
| 2024-08-14 | Notification Of Non-Final Action E-Mailed |
| 2024-06-15 | New Application Office Supplied Data Entered |
| 2024-06-15 | Notice Of Design Search Code E-Mailed |
| 2024-01-19 | New Application Entered |
Goods & services
Class 5 Pharmaceuticals & supplements
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, inflammatory, namely except inflammatory bronchial disease, metabolic, neurodegenerative, neurological, psychiatric, oncological, and viral diseases and disorders; Pharmaceutical preparations for the treatment of liver diseases and disorders, erectile dysfunction, sexual dysfunction, cancer, pain, and diabetes; Reagent paper for medical purposes
Class 42 Technology & SaaS
Pharmaceutical research and development, namely, pharmaceutical testing, inspection and research
Class 44 Medical & beauty services
Medical information; Providing health care information via a global computer network
Source & freshness
Source: USPTO Trademark Applications bulk data. This record was last updated by the USPTO file dated 18 Aug 2026; the index was built on 20 Nov 2026 and covers USPTO data through 31 Aug 2026. Open the official USPTO record (TSDR) → If the two differ, the USPTO record is correct.